Next Generation Capsule Endoscopy Video Data Acquisition and Visualization Platfo

描述（由申请人提供）：胃肠道（GI）恶性肿瘤是世界上最常见的癌症原因。全世界每年有1080万人患癌症，其中约330万人患有胃肠道恶性肿瘤。除了预防之外，迫切需要有效、低成本和舒适的早期诊断技术来改善这种情况。传统的内窥镜或放射性成像方法给患者带来明显的不适，成本高，或缺乏灵敏度。目前的胶囊式内窥镜（CE）成像技术代表了重大的技术突破。但是，它仍然存在诸如无效的前视FOV和差的图像质量的缺点，并且要求长的诊断查看时间。Altrum Technologies，Inc.与马约诊所合作，在该SBIR项目中提出为下一代CE技术开发一种新型光学成像胶囊和视频数据可视化/分析硬件/软件系统，称为GISentinelTM。GIStinel基于我们正在申请专利的360度成像光学器件，具有独特的图像展开和强大的全景配准技术，将具有以下临床影响和意义：3/4用于GI成像的蛙跳技术：作为一种可吞咽的药丸，GIStinel胶囊提供即时的360 °图像，不受胃肠道组织壁的机械影响，因此不会给患者带来不适-不再有传统内窥镜的管插入所带来的镇静或疼痛。 3/4没有遗漏的胃肠道疾病区域：GIStinel胶囊提供了一个完整的360 °胃肠道周围，没有任何区域会被遗漏。 3/4准确快速的诊断：通过更有效的图像配准，GIStinel SW有望帮助GI医生/护士快速（最短0.5小时）准确诊断异常。 3/4低成本的胶囊系统，更好地获得大众的接受和有效的疾病预防：由于其简单的结构和光学设计，GIStinel胶囊的制造成本约为55美元，如果数量超过1000。 3/4可扩展和可升级的技术：为GIStinel开发的专有全方位技术可轻松应用于现有诊断仪器（内窥镜，结肠镜，胃镜，千禧年研究小组预测，2008年仅在美国，胶囊式内窥镜市场的收入就将超过5亿美元，而2008年仅在美国，胶囊式内窥镜市场的收入就将超过5亿美元。2004年4000万。根据Given Imaging Ltd.的说法，全球有近100万患者使用PillCam胶囊进行了胶囊式内窥镜检查。胶囊式内窥镜是一个快速增长的数十亿美元的市场。拟议的地理信息系统试点系统和技术的商业化潜力很大。 公共卫生相关性：在SBIR项目下开发的GISentinelTM系统和技术将为胃肠道患者提供一种低成本和非侵入性的早期胃肠道疾病诊断和预防方法。GIStinel提供了一种创新的全景成像和镶嵌技术，可以缩短诊断时间，获得更准确的结果。凭借目前药丸相机的扩展功能，GIStinel预计将在这个数十亿美元的行业中占据相当大的市场份额。此外，GIStinel技术还将使非医疗领域受益，如商业周边监控以及水和天然气管道检查。

DESCRIPTION (provided by applicant): Gastrointestinal (GI) malignancies are the most common cause of cancer in the world. Of the 10.8 million people in the world each year who develop cancer, approximately 3.3 million have GI malignancies. Aside from prevention, effective, low cost, and comfortable early diagnosis technologies are urgently needed to improve this situation. Traditional endoscopic or radioactive imaging methods present significant discomfort to the patients, is costly, or lack sensitivity. Current capsule endoscopy (CE) imaging technique represents great technological breakthrough. However, it still has drawbacks such as ineffective forward looking FOV and poor image quality, and requests long diagnosis viewing time. Altrum Technologies, Inc. in collaboration with Mayo Clinic proposes in this SBIR project to develop a novel optical imaging capsule and video data visualization/analysis hardware/software system called GISentinelTM for the next generation CE technology. Built on our patent pending 360 degree imaging optics, with unique image unwrapping and robust panoramic registration techniques, GISentinel will have the following clinic impact and significance: 3/4 A leapfrog technology for GI imaging: Used as a swallowable pill, GISentinel capsule offers instant 360o images mechanically free for GI tract tissue wall, thus causing no discomfort to patients - no more sedation or pain from the tube insertion of traditional endoscopes. 3/4 No missing GI disorder areas: GISentinel capsule offers a complete 360o surrounding of the GI tract, no area will be missed. 3/4 Accurate and rapid diagnosis: Through more effective image registration, GISentinel SW is expected to help GI doctors/nurses to rapidly (down to 0.5 hours) and accurately diagnose abnormalities. 3/4 A low cost capsule system for better mass acceptance and effective disease prevention: Due to its simple structural and optical design, GISentinel capsule can be manufactured at a cost of around $55 if over a quantity of 1000. 3/4 Expandable and scalable technology: The proprietary omni-directional technology developed for GISentinel can be easily applied to existing diagnosis instruments (endoscopes, colonscope, gastroscope, etc) to provide similar benefits to the patients The Millennium Research Group predicated the capsule endoscopy market is to generate more than $500 million in 2008 in the United States alone - up from just $40 million in 2004. According to Given Imaging Ltd., close to 1 million patients worldwide have gone through capsule endoscopy procedures using their PillCam capsules. Capsule endoscopy is a rapidly-growing multi-billion dollar market. The commercialization potential of the proposed GISentinel system and technology is significant. PUBLIC HEALTH RELEVANCE: The GISentinelTM system and technology developed under this SBIR project will provide great benefit to GI patients by providing a low cost and non-invasive method for early GI tract disease diagnosis and prevention. GISentinel provides an innovative panoramic imaging and mosaic technique leading to much shorter diagnosis time with more accurate results. With the extended capability over current pill cameras, GISentinel is expected to have a reasonably large market share of this multi-billion dollar industry. In addition, GISentinel technology will also benefit non-medical fields such as commercial perimeter surveillance, and water and gas pipe inspection.